Skip to content

Serotonin: all studies

Page 263 of 401: studies 2,621 to 2,630 of 4,006, newest first. Back to the serotonin overview

Research

The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression

Frontiers in Psychiatry September 19, 2023 Nicolas Garel, Jessica Drury, Julien Thibault Lévesque et al. 32 citations

Background Subanesthetic ketamine has accumulated meta-analytic evidence for rapid antidepressant effects in treatment-resistant depression (TRD), resulting in both excitement and debate. Many unanswered questions surround ketamine’s mechanisms of action and its integration into real-world psychiatric care, resulting in diverse utilizations that variously resemble electroconvulsive therapy,...

DOI: 10.3389/fpsyt.2023.1268832 (opens in new tab) Ketamine Biopsychosocial model Psychotherapist Clinical psychology

Psychoactive substances 25H-NBOMe and 25H-NBOH induce antidepressant-like behavior in male rats.

European Journal of Pharmacology September 15, 2023 Barbara G Ferri, Cintia O De Novais, Raquel S Bonani et al. 11 citations

Ring-substituted phenethylamines are believed to induce psychedelic effects primarily by interacting with 5-hydroxytryptamine 2 (5-HT2A) receptors in the brain. We assessed the effect of the psychedelic substances 25H-NBOMe and 25H-NBOH on the depressive-like behavior of male adult rats. Naive Wistar rats were divided into groups to assess the effects of different doses (0.1 mg/kg, 1 mg/kg, and...

Discovery and In Vitro Characterization of SPL028: Deuterated N,N-Dimethyltryptamine.

ACS Medicinal Chemistry Letters September 14, 2023 Marie Layzell, Peter Rands, Meghan Good et al. 6 citations

The psychedelic N,N- dimethyltryptamine (DMT) is in clinical development for the treatment of major depressive disorder. However, when administered via intravenous infusion, its effects are short-lived due to rapid clearance. Here we describe the synthesis of deuterated analogues of DMT with the aim of prolonging the half-life and decreasing the clearance rate while maintaining similar...

DOI: 10.1021/acsmedchemlett.3c00143 (opens in new tab) Full text (opens in new tab) Psychedelics Drug development Mental health treatment Pharmaceutical research

Classic Psychedelics for the Treatment of Depressive Disorders: An Update for Psychiatrists in Training

American Journal of Psychiatry Residents Journal September 8, 2023 Lawrence Canale, Dhvanit Raval, Preet Chatha et al.

Psychedelics as therapeutic agents have generated significant attention from clinicians and media sources in recent years. The authors provide an update to the psychiatric trainee on the evidence for psychedelics in the treatment of major depressive disorder and treatment-resistant depression. Many modern clinical trials of the classic, serotonergic psychedelics, such as psilocybin, ayahuasca,...

Evolving antidepressant: from SSRIs to psychedelic

International Conference on Modern Medicine and Global Health September 7, 2023 H. Hong

SSRIs mediate antidepressant effects by inhibiting specific serotonin transport(SERT) and subsequent modulation of serotonin levels in the brain. This review paper provides an overview of the mechanisms of action of selective serotonin reuptake inhibitors (SSRIs), as well as psychedelics, including their potential therapeutic applications in treating psychiatric disorders. By examining the...

Potential Benefits of Psilocybin for Lupus Pain: A Case Report

Current Rheumatology Reviews September 6, 2023 Christine Alexopoulos, Sofia Audrey B. Gonzales, Daniel G. Arkfeld 6 citations

Introduction: Outcomes of treatment for patients with Lupus have shown overall improvement and benefit from the more aggressive use of immunosuppressants and biological agents through a treat-to-target approach. However, chronic musculoskeletal pain can be refractory to treatment despite the use of non-steroidal anti-inflammatory drugs, corticosteroids, and other analgesic agents, leading to...

DOI: 10.2174/1573397119666230904150750 (opens in new tab) Psilocybin Chronic pain Systemic lupus erythematosus Neuropathic pain +6

EVALUATION OF THE THERAPEUTIC NEUROTOXIC EFFECTS OF THE USE OF AYAHUASCA BY DEPRESSIVE PATIENTS

Revista Contemporânea September 5, 2023 Catarina Rodrigues Damasceno Murucci, Rita de Cássia Ramos Queiroz de Freitas, Grazielly Ribeiro Viana et al.

Ayahuasca is a tea used in original indigenous rituals with the aim of expanding the mind and consciousness. Some studies have pointed to Ayahuasca as a potent antidepressant with reduced side effects when compared to other conventional synthetic allopathic treatments. Over the years, tea has come to be known by both the popular community and the scientific community. The species used are...

DOI: 10.56083/rcv3n9-011 (opens in new tab) Ayahuasca Pharmacology Harmaline Traditional medicine +1

Striatal Iron Deposition in Recreational MDMA (Ecstasy) Users.

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging September 2023 Rebecca C Coray, Jatta Berberat, Josua Zimmermann et al.

The common club drug MDMA (also known as ecstasy) enhances mood, sensory perception, energy, sociability, and euphoria. While MDMA has been shown to produce neurotoxicity in animal models, research on its potential neurotoxic effects in humans is inconclusive and has focused primarily on the serotonin system. We investigated 34 regular, largely pure MDMA users for signs of premature...

Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics.

Molecular Psychiatry September 1, 2023 Alaina M Jaster, Javier González-Maeso 50 citations

Psychedelics, also known as classical hallucinogens, have been investigated for decades due to their potential therapeutic effects in the treatment of neuropsychiatric and substance use disorders. The results from clinical trials have shown promise for the use of psychedelics to alleviate symptoms of depression and anxiety, as well as to promote substantial decreases in the use of nicotine and...

Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.

Neuropsychopharmacology September 1, 2023 Guy M. Goodwin, Megan Croal, David Feifel et al. 166 citations

Psilocybin is being investigated as a treatment in adults with treatment-resistant depression (TRD). Withdrawal from serotonergic antidepressant drugs is a common prerequisite for taking part in trials of psilocybin due to the possibility of ongoing antidepressant drugs altering the psychedelic effect. This phase II, exploratory, international, fixed-dose, open-label study explored the safety,...